Rheumatism Patients' COVID antibodies under the microscope
NCT ID NCT04530682
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 163 people with chronic inflammatory rheumatism (like rheumatoid arthritis) who had a recent COVID-19 infection. Researchers measured their antibody levels over two years to see how immunosuppressive drugs affect antibody persistence. The goal was to better understand immune protection and guide vaccination strategies for this group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY RHEUMATISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre hopsitalier universitaire de Montpellier
Montpellier, Occitanie, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a gut microbiome transplant ease axial spondyloarthritis?
- Can group learning make biotherapy safer for arthritis patients?
- Gentle tai chi may get spondyloarthritis patients moving
- Immune clues in the blood may foretell heart trouble
- Can a 4-Minute chat rival a Dietitian's hour for heart health?
- Could low vitamin c explain lingering pain in rheumatism and lupus?